| Name | Title | Contact Details |
|---|
GenSight Biologics is is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics` pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics` lead product candidate, GS010, is in Phase III trials in Leber`s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics` product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.
Enthalpy Analytical, Inc. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nile Therapeutics is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RDMD`s mission is to empower patients and communities to accelerate the development of treatments for rare diseases of all kinds.